



---

# Drug Discovery and Development Consultants Ltd

**An introduction:  
Who we are and what we do**

For more information please visit <https://www.3dconsultants.org.uk/contact>.

---



# Overview

A scientific consultancy based upon the partnership's capability to provide a specialist solution for those looking for expert advice and support across all aspects of drug discovery and development

**Core competencies** of the 3D Consultants team :

- *In vitro/in vivo* biology
- Medicinal chemistry
- Preclinical development (DMPK, CMC, tox, scale-up, clin pharm)
- Clinical development (translational medicine, clin ops, regulatory approval)

**As a team having worked together for many years on large multidisciplinary projects, we can provide efficiencies in ensuring cost-effective and timely delivery of our clients' objectives**



# Our History So Far

- Company was founded in June 2018 in Cambridge UK
- Currently have 13 consultants in the partnership
- We have worked with a broad range of clients including:

BenevolentAI



*The company names and logos are the trademarks or registered trademarks of the third party clients named*

# Our Expertise



**M Pritchard I Gonzalez M Higginbottom**



**Discovery Sciences**  
Med Chem, CMC, *in Vitro/in Vivo* Biology

**B Pullman**



**Translational Medicine**  
Clin Pharm, Dev and Regulatory Sciences

**M Ashwood S Burbidge B Campbell**



**Pre-Clinical Development**  
DMPK, CMC, Tox, Project Management

**S Snape A Morgan M Duffy H Done**



**Clinical Development**  
Trial design, management and operations

**T Sparey B Hardiman**



**Business and Corporate Development, fundraising**

# Experience Across Pharma and Biotech



- The 3D Consultants team has worked together in companies including GSK, Novartis, Pfizer, Parke-Davis, Proximagen and Cambridge Biotechnology Ltd/Biovitrum
- Broad understanding of, and direct experience in working across, a wide range of therapeutic areas, mechanisms of action and molecular targets
- Our consultants have held key executive positions including CEO, research director, head of site, VP and functional area heads of med chem, biology and clinical development - broad experience in managing companies.



CBT/Biovitrum



PROXIMAGEN

# Disease Area Focus

- The consultancy partnership has skill sets and broad experience relevant across a variety of therapeutic areas extending from early discovery phase through into clinical development
  - Particular focus and extensive experience in CNS, pain and inflammation
  - Also direct experience in neurodegeneration, cognition, IBD, metabolism and cancer
  - Broad clinical expertise but with focus on rare diseases, genetic disorders, drug repurposing, paediatric medicine and drug device development

# Our Collective Experience

- Identification and prioritisation of drug targets and technologies
- Drug discovery activities through hit ID, LG, LO and candidate nomination
- Non-clinical development campaigns: pharmacology, DMPK, drug candidate scale-up, CMC, process development, exploratory and GLP tox
- Programme leadership/management/budget/project planning
- Executing projects as a virtual team from discovery through Phase 2 PoC
- Clinical Operations for First in Human and Phase 2 PoC
- Quality Management Systems, regulatory and QA advice
- In-licensing and out-licensing activities including due diligence support
- Working in partnerships with big pharma, biotechs and CROs
- Company start-ups and sales including the preparation of business plans

# Exemplar Case Histories

- **Operational support** for the management of a first in human Phase I study and follow on Phase II clinical study
- **Provision of biology and med. chem. support** for a NewCo raising funds for a discovery phase screening campaign to identify novel chemotypes.
- **Supporting academia-based PIs** introduced by a US charity in project planning for both discovery and pre-clinical phase programmes.
- **Project management** of a pre-clinical phase programme for a client looking to take novel compounds into the clinic.
- **Review of literature and proprietary data package** for investment fund manager of early stage pre-clinical asset of a potential NewCo.
- **Generation of a report and top line BP** to potential investors for repurposing of a clinical stage asset



# Our Services and Deliverables

## Project Leadership and Project Management/Mentoring

- Leading and managing projects from target ID through to clinical phases
- Support in accessing an extensive network of trusted CROs

## Due Diligence

- Broad experience in carrying out due diligence campaigns to support in-licencing/out-licencing assets, technologies and companies
- Provision of competitive landscapes for targets, diseases, drugs, funding, deals and companies using commercial databases

## Supporting Company Start-Ups and Sales

- Experience as CEOs, directors and founders of start-ups and thus able to support starting/selling companies (including fundraising campaigns)



# Representative Testimonials

- “3D consultants have provided us with timely, high quality consultancy with the exact skills we required and a flexibility reflecting early stage life sciences operations. We would highly recommend” **Closed Loop Medicine, UK**
- “We have the privilege of recommending 3D Consultants based on our long-standing professional interactions with them. 3D consultants are highly experienced scientists with competencies across core drug discovery, preclinical development, and early clinical development disciplines. Without reservation we are happy to recommend 3D consultants for their scientific expertise, decision making prowess, high professional integrity in delivering quality work, and for their responsiveness and commitment to our urgent timelines.” **Proximagen LLC, USA**
- “3D provided us with project management and operational support for a first in human Phase I study. The practical experience of 3D was obvious from the start with an ability to immediately integrate into our team and work effectively with external CROs in a cooperative and productive manner to deliver the study on time and in budget. “I have previously worked with the 3D team and know from direct experience that they take a hands-on, pragmatic approach to early drug development, drawing on a wealth of experience to deliver results” **CEO of European Biotech**
- “Engaging 3D at the Tau Consortium has provided us with deep pharmaceutical and drug discovery expertise, critical as we take our drug discovery portfolio from Academia to a rigorous drug discovery setting. Their multidisciplinary approach has proven very useful in performing due diligence on a set of projects, where that collective expertise was critical. We are looking to continue to engage 3D on oversight of integrated drug discovery programs working with external CROs and collaborators. 3D takes a hands-on, pragmatic approach that draws on a wealth of experience to deliver results”. **Tau Consortium/Rainwater Charitable Foundation, USA**



# How We Can Help You

- Our team benefits from many years experience of **working together** and leading project teams in both pharma and biotech
- The team has a successful and broad track record of delivering **drug candidates** through into clinical phases
- Our consultants have expertise and experience across a broad range of disease areas, with a focus on the **CNS, inflammation and pain**
- We are able to provide a point source of skill sets capable of providing **leadership, support and mentoring** to project teams from target ID through to clinical development planning and operations

**We can support you in transforming breakthrough discoveries into drugs**

For more information please visit <https://www.3dconsultants.org.uk/contact>.

# Supporting Slides

# The 3DConsultants Team

## Directors



**Martyn  
Pritchard**  
**Director**

Discovery and  
Dev. Chemistry



**Isabel  
Gonzalez**  
**Director**

Discovery  
Biology



**Stephen  
Burbidge**  
**Director**

Discovery and  
Pre-clinical Projects

Please see biographies on our website:  
<https://www.3dconsultants.org.uk/team>

Confidential

# Stephen Burbidge, BSc, PhD



**GLAXO-WELLCOME,  
Stevenage**  
Research Scientist  
(Discovery Research)

**GSK, Harlow**  
Senior Team Leader  
(Neurodegeneration  
Research)

**PROXIMAGEN,  
Cambridge**  
Head of Preclinical  
Development

1995-96

1996-2001

2001-03

2003-08

2006-2008

2009-18

2018-present



BSc,  
PhD

**LUDWIG INSTITUTE FOR  
CANCER RESEARCH**  
St Mary's Hospital,  
London  
Post-doctoral Scientist



**GSK, Harlow**  
Team Leader  
(Migraine and  
Stroke Research)



**GSK, Centre of  
Excellence for External  
Drug Discovery (CEED)**  
Senior Research  
Leader

**3D CONSULTANTS**  
Director



Confidential

# Martyn Pritchard, BSc, PhD



University of  
Wales  
PhD Organic  
Chemistry



PARKE-DAVIS  
People Who Care


PARKE-DAVIS  
Neuroscience Res.  
Cent., Cambridge  
Senior Research  
Chemist

CBT/Biovitrum

Cambridge  
Biotechnology Ltd,  
Cambridge  
Head of Med Chem;  
Head of R&D

PROXIMAGEN

PROXIMAGEN,  
Cambridge (acquired  
by BAI in 2018)  
Head of R&D



University of  
Southampton  
Postdoctoral  
Fellow



PFIZER,  
Cambridge  
Senior Research  
Chemist



PROXIMAGEN,  
Cambridge  
Consultant



3D CONSULTANTS  
Director



Confidential

# Isabel Gonzalez, BSc, MSc, PhD



**COMPLUTENSE UNIV, Madrid**  
Lecturer (Animal Physiology)



**PARKE-DAVIS**  
Neuroscience Res Cent., Cambridge  
Group Leader



**NOVARTIS, London**  
Laboratory Head,  
Pharmacology



**PROXIMAGEN, Cambridge**  
Head of Biology

1994-97

1997-2000

2000-01

2001-02

2002-08

2009-18

2018-present

**ST GEORGE'S HOSPITAL, London**  
Post-doctoral  
Research Fellow

**PFIZER, Cambridge**  
Senior Group Leader

**GSK, Harlow**  
Senior Team Leader,  
Neurodegeneration

**3D CONSULTANTS**  
Director



Wolfson College  
Cambridge



# Stephen Burbidge

## Director, Discovery and Preclinical Projects

**Dr Stephen Burbidge** has over 20 years experience within the pharmaceutical industry, working in both biotech and large multi-national pharma organisations, including GlaxoWellcome and GlaxoSmithKline. From 2009 he worked at Proximagen Ltd, where he held the role of Head of Discovery and Preclinical Projects for the last four years. During this period, he led multiple Discovery and preclinical stage programmes leading to the selection of multiple clinical candidates, including a VAP-1 inhibitor which is now in Phase 2 clinical development, licensed to Roche. Dr Burbidge supported all preclinical activities at Proximagen, including executing multiple non-GLP and GLP toxicology studies and supporting due diligence. Dr Burbidge has authored a number of publications. He received his BSc and PhD from the University of Warwick (UK).



# Isabel Gonzalez

## Director, Discovery Biology

**Dr Isabel Gonzalez** has over 30 years of research experience, resulting in more than 50 publications. She combines 12 years experience in University research laboratories and 20 years of experience in the pharmaceutical industry, in three different multinational companies (Parke-Davis/Pfizer, Novartis and GSK) and one biotechnology company (Proximagen, currently BenevolentAI), where she was Head of Biology for the last 9 years. Isabel specialises in the areas of pain, inflammation and neurodegeneration and she has been a successful project leader, with a proven track record of achievements across all these organisations. She has a deep knowledge of all Home Office licences and regulations. Isabel is a Graduate of the Universidad Complutense, Madrid (Spain) where she studied biology and completed a PhD in Animal Physiology in 1990.



# Martyn Pritchard

## Director, Discovery and Development Chemistry

**Dr Martyn Pritchard** was head of R and D at Proximagen from 2012 through to its acquisition in early 2018, where he was responsible for managing almost 50 scientists, an annual budget of ~£15M and programmes spanning from early discovery through to Phase 2. Prior to his years at Proximagen he was a founding member of Cambridge Biotechnology Ltd, where he was a key member of the team responsible for raising over £10M in investment funding and managing its subsequent acquisitions by Biovitrum,, Proximagen and Upsher Smith. Martyn is a Graduate of the University of Wales, Swansea, studying chemistry and completing a PhD in organic chemistry in 1985 before undertaking Postdoctoral Fellowships in Southampton and Cambridge. Martyn is an author of over 50 papers and is a named inventor on in excess of 20 patents.



# Tim Sparey

## Associate, Business Development

**Dr Tim Sparey** is a serial entrepreneur with over 24 years of experience in large pharma and biotech companies. He is a medicinal chemist by background and spent 11 years in CNS R&D with Merck & Co before moving on to work in their BD&L team sourcing and evaluating technologies in all disease areas. Since leaving Merck & Co he has held board level, C-suite CEO and CBO positions in four biotech companies. In these roles he built, developed and transacted in multiple disease areas including CNS, inflammation, ophthalmology and cancer in deals totalling over \$1bn in value. His biotech experience is in private and public companies including Proximagen (CBO), Q Chip (CEO) and Midatech (CBO). Tim is currently the CEO and co-founder of Novintum, Tim also advises numerous groups including Deep Science Ventures and consultancy clients on strategy, corporate development, fundraising and business development.



# Case Studies I


The 3D team has worked on a variety of contracts for a range of clients from investment fund managers to pharma companies and include the following as examples of the work undertaken -

- Operational support for the management of a first in human Phase I study
- Operational support of asset in Phase II clinical development
- Preclinical support and management of GLP tox-ready project
- Due diligence review of pre-clinical package and CMC sections of a potential in-licencing asset
- Providing due diligence as well as supporting PIs/projects/grant proposals for a US-based charity focusing on neurodegeneration

# Case Studies II

- Generation of a report and presentation to potential investors for repurposing of a clinical stage asset with inclusion of business plan, timelines and budget to clinical milestones.
- Provision of mechanism of action rationale, current status and potential future development options to support additional indications of a novel CNS drug candidate.
- Literature review of potential new indication of an existing asset with a novel mechanism of action.
- Review of literature and proprietary data package for investment fund manager of early stage pre-clinical asset of a potential NewCo.

# CRO Network: Discovery



# CRO Network: Development

